Xunqing Jiang
Overview
Explore the profile of Xunqing Jiang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
458
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rahman M, Bissa M, Scinto H, Howe S, Sarkis S, Ma Z, et al.
Nat Commun
. 2024 Oct;
15(1):9102.
PMID: 39438480
Systemic vaccination of macaques with V1-deleted (ΔV1) envelope immunogens reduce the risk of SIV acquisition by approximately 60%, with protective roles played by V2-specific ADCC and envelope-specific mucosal IL-17NKp44 innate...
2.
Upadhyay C, Rao P, Behzadi M, Feyznezhad R, Lambert G, Kumar R, et al.
Front Immunol
. 2024 Oct;
15():1476924.
PMID: 39380992
Introduction: HIV-1 envelope (Env) is the key target for antibodies (Abs) against the virus and thus an important HIV-1 vaccine component. Env is synthesized from a gp160 precursor with a...
3.
Hioe C, Liu X, Banin A, Heindel D, Klingler J, Rao P, et al.
Front Immunol
. 2023 Nov;
14:1329069.
PMID: 38022586
[This corrects the article DOI: 10.3389/fimmu.2023.1271686.].
4.
Hioe C, Liu X, Banin A, Heindel D, Klingler J, Rao P, et al.
Front Immunol
. 2023 Oct;
14:1271686.
PMID: 37854587
Introduction: Neutralizing antibodies (Abs) are one of the immune components required to protect against viral infections. However, developing vaccines capable of eliciting neutralizing Abs effective against a broad array of...
5.
Xu Y, Ferguson T, Masuda K, Siddiqui M, Smith K, Vest O, et al.
Biomolecules
. 2023 Jul;
13(7).
PMID: 37509124
Developing a safe and effective preventive for HIV-1 remains the hope for controlling the global AIDS epidemic. Recently, mRNA vaccines have emerged as a promising alternative to conventional vaccine approaches,...
6.
Xu Y, Jiang X, Zhou Z, Ferguson T, Obliosca J, Luo C, et al.
Part Part Syst Charact
. 2022 Oct;
39(5).
PMID: 36186663
The HIV-1 envelope glycoprotein spike is the target of antibodies, and therefore represents the main viral antigen for antibody-based vaccine design. One of the challenges in HIV-1 vaccine development is...
7.
Xu Y, Zhou Z, Brooks B, Ferguson T, Obliosca J, Huang J, et al.
Front Immunol
. 2022 Sep;
13:900080.
PMID: 36059505
Developing a safe and effective malaria vaccine is critical to reducing the spread and resurgence of this deadly disease, especially in children. In recent years, vaccine technology has seen expanded...
8.
Britton D, Punia K, Mahmoudinobar F, Tada T, Jiang X, Renfrew P, et al.
Biochem Eng J
. 2022 Aug;
187:108596.
PMID: 36034180
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic since December 2019, and with it, a push for innovations in rapid testing and neutralizing antibody treatments in...
9.
Weiss S, Itri V, Pan R, Jiang X, Luo C, Morris L, et al.
Nat Commun
. 2022 Feb;
13(1):903.
PMID: 35173151
V2p and V2i antibodies (Abs) that are specific for epitopes in the V1V2 region of the HIV gp120 envelope (Env) do not effectively neutralize HIV but mediate Fc-dependent anti-viral activities...
10.
Hessell A, Li L, Malherbe D, Barnette P, Pandey S, Sutton W, et al.
J Immunol
. 2021 Feb;
206(6):1266-1283.
PMID: 33536254
The role of vaccine-induced anti-V2 Abs was tested in three protection experiments in rhesus macaques. In an experiment using immunogens similar to those in the RV144 vaccine trial (Anti-envelope [Env]),...